INNOVATING WELLNESS RELIEF

Similar documents
Minnesota Medical Cannabis Program. October 24, 2017

Medical Marijuana Update

Table of Contents. Overview 3 Eligibility 3

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018

North Central Florida Regional Planning Council

MINNESOTA S MEDICAL CANNABIS PROGRAM

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

Agracan - LP. Palmerston Industrial Park Cannabis Cultivation Facility

Medical Cannabis Ordinances. Tuesday, December 20, 2016

MEDICAL CANNABIS IN MINNESOTA

DESCRIPTION DURATION

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

PATIENT INTAKE FORM. Name: Address: Town: State: Zip Code: MMJ Card #: Exp. Date: Drivers License #: Exp. Date: Home Phone: Cell:

MEDICAL CANNABIS IN MINNESOTA

The Company. Beyond Pioneering

The Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association

Medical Cannabis Program. Dr. Maureen Small Co Medical Director Andrea Sundberg Program Coordinator

Medical Marijuana and Student Health. New England College Health Association Gordon H. Smith, Esq. October 30, 2014

Reefer Mania: The State of Medical Marijuana in Florida

Ohio s Medical Marijuana Control Program

In New York State. Highly Worth It OR Not??? Medical Marijuana. The Truths 3/29/2018. True or False???

Outcome. Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

ASSEMBLY APPROPRIATIONS COMMITTEE STATEMENT TO. ASSEMBLY COMMITTEE SUBSTITUTE FOR ASSEMBLY, No STATE OF NEW JERSEY DATED: APRIL 5, 2018

City Commission Agenda Cover Memorandum

Be it enacted by the People of the State of Illinois,

What Cities Need to Know about the Arkansas Medical Marijuana Amendment ( AMMA ) 1

Coordinated Student Health Services. Medical Marijuana/ Low THC Cannabis Use To Qualified Students In Schools Policy

INITIAL PATIENT INTAKE FORM

Constance Finley Founder and CEO

City of Coral Gables Planning and Zoning Staff Recommendation

Medical Marijuana Update Chris Belletieri, DO

Compassionate Medical Cannabis: What It Means to the Street Officer

WELCOME TO THEORY WELLNESS PATIENTS. Committed to wellbeing through cannabis.

ENROLLED 2014 Legislature CS for CS for SB 1030, 1st Engrossed

HEALTH WELLNESS COMMUNITY

Substitute HB 523 Outline

Arkansas Municipal League. What Cities Need to Know about the Arkansas Medical Marijuana Amendment

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 1030

MEMORANDUM. DATE: November 19, Senator Kohl-Welles. Kathleen Buchli, Counsel medical marijuana proposal

Medical Marijuana Consent Form

WELCOME TO THEORY WELLNESS CUSTOMERS. Committed to wellbeing through cannabis.

ORDINANCE NO

The Legalization of Medical Marijuana and the Impact on the Workplace

Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD

Pennsylvania s Medical Marijuana Program

Therapeutic Cannabis Law Physician Issues

SUPER SNOUTS CBD150 & CBD300 OIL FOR DOGS & CATS

CDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only

Global Legal Cannabis Market: Size, Trends & Forecasts ( ) September 2018

Marijuana: Laws Allowing the Limited Use of Low-THC Oil for Medicinal Purposes

Medical Marijuana: Florida Law Overview & The Impact on Commercial Real Estate

Medical Marijuana: Current Policies and Consideration. By Michael Bertaut Healthcare Economist, BCBSLA 2019

Pennsylvania s Medical Marijuana Program

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

Medical Cannabis and OMT

Medical Marijuana for Pain How Does Cannabis Work on Your Body?

WHO WE ARE PROVIDING YOU WITH SUPREME CBD PRODUCTS SINCE 2011.

Is the most common illicit drug used in the United States. After a period of decline in the last decade, its use has been increasing among young

THE STATE OF THE STATES-A REPORT ON MEDICAL CANNABIS PROGRAMS MID YEAR MEETING AND SCIENTIFIC SEMINAR APRIL 13, 2018 NASHVILLE, TENNESSEE DEBBY MIRAN

TEXAS COMPASSIONATE-USE ACT

Research: Medical Cannabis

Clinical Challenges and Political Uncertainty

VA P I N G + R E D E F I N E D

Cannabis and What we Know. Bonnie Schnittker RN PHN Public Health Nurse October 20, 2017

Susan Audino, PhD S.A. Audino & Associates, LLC

PATIENT GUIDE TO MEDICAL CANNABIS

OREGON MEDICAL MARIJUANA ACT

Clinical Education Initiative MEDICAL MARIJUANA 101. Speaker: Patricia Reed, PharmD

December 2018 Brief Explanation of Proposition 2 and Compromise Bill Passage

Oregon Medical Marijuana Dispensary Program. Thomas A. Burns Director Pharmacy Programs Oregon Health Authority

Australian Medicinal Cannabis Pricing Analysis

Requirement for Certification from a Health Care Practitioner. Requirement for Certification from a Health Care Practitioner

1 Hartford Square, New Britain, CT Armen Paronyan, CEO Jason Kang, Founding Member Jose Zavaleta, Lab Director

MEMORANDUM. City Council. Alfred D. Lott, ICMA-CM, CPM City Manager. SUBJECT: Status Report/Council Poll DATE: March 14, 2019.

Welcome to MedWell. MedWell Health and Wellness Centers. Don t live with PAIN Live WELL MedWell. o Newspaper o Referred by.

Medical Marijuana. 1. is a plant species, variety known as hemp. 3. Tetrahydrocannabinol is an aromatic with low water solubility.

Medical Cannabis: A Patient Primer

natal Marijuana and Public Health: The Colorado Perspective

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

ACS. Quality, Integrity, Safety. Our logo says it all

CERTIFICATION OF ENROLLMENT ENGROSSED SUBSTITUTE SENATE BILL th Legislature 2007 Regular Session

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014

Enter the Cup; The Official Rules, Regulations & FAQ

James Donaldson CEO and Executive Director

BRIDGEWATER PRODUCT MENU. Current as of

Comprehensive Cannabis Curriculum

Title 18 Chapter 86 Therapeutic Use of Cannabis 2013 Annual Report

STATUS OF THE NEW CANNABIDIOL PROGRAM

Department of Public Safety

A P P E N D I X B : H E A T L H C A R E P R A C T I T I O N E R - R E P O R T E D B E N E F I T S F R O M S U R V E Y S

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

New York. Prescribing and Dispensing Profile. Research current through November 2015.

Membership Package Checklist

NEW. 5 Pack PRE ROLLS. NETACares TOY DRIVE

Cannabis & Hemp therapeutic solutions

Medical vs Recreational Use of Cannabis. 11 th December 2017

Leading a budding industry into the future

Transcription:

INNOVATING WELLNESS RELIEF When Florida passed the original law that individuals with debilitating medical conditions (as determined by a licensed Florida physician) could be approved to utilize medical cannabis, Knox Nursery with the support, guidance, and leadership of Cansortium Holdings created Knox Medical ( Knox ). Knox is a Florida based organization that scored higher than any other applicant to become 1 of 5 Dispensing Organizations, authorized to cultivate, process and dispense CBD and medicinal cannabis products. While our corporate oice is based in Miami, our nursery is centrally located in Winter Garden, Florida. Under the leadership of our Chief Cultivation Oicer, Bruce Knox, Knox Nursery is the home of our cultivation and processing center. Knox has invested in the latest technology to support our production of medicinal cannabis products. Our propietary extraction equipment was designed Knox has invested in the latest technology to support our production of medicinal cannabis products. by retired NASA engineers and our greenhouse cultivation area is supported by radiofrequency identification technology. This allows us to collect data scans from an individual unit to the entire production environment. Knox has established rigorous purity standards by investing in stateof-the-art technology capable of providing the most advanced analytical testing in the areas of potency, pesticides, residual solvents, heavy metals, microbiologicals, terpenes, aflatoxins, and ochratoxins. Knox has successfully developed a leadership team of horticulture, healthcare, pharmacy, retail, legal, compliance, government aairs, investor relations, and public aairs experts to develop and manage our daily operations. At Knox, our quality, standards, practices, performance, and team of associates are unmatched.

WELLNESS GUIDELINES Currently, the State of Florida requires that a patient establish a minimum of a 90-day relationship with a qualified ordering physician registered with the Oice of Compassionate Use. Only a qualified ordering physician can determine if the patient meets the criteria to be recommended for CBD and/or medicinal cannabis. Studies have shown that medicinal cannabis is instrumental in the successful treatment of a number of medical and behavioral health conditions. In 2016, Floridians overwhelmingly approved Amendment 2 which authorized the use of medical marijuana for the treatment of the following medical conditions: f f Acquired Immune Deficiency Syndrome (AIDS) f f Amyotrophic Lateral Sclerosis (ALS) f f Cancer f f Crohn s Disease f f Epilepsy f f Glaucoma f f Positive Status for Human Immunodeficiency Virus (HIV) f f Parkinson s Disease f f Post-Traumatic Stress Disorder (PTSD) f f Multiple Sclerosis (MS) f f As well as any other debilitating medical condition of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of cannabis would likely outweigh the potential health risks for a patient.

TREATMENT IN ABOUT US CROHN S DISEASE GLAUCOMA AIDS THC CANCER CBD & THC BEST STRAINS FOR TREATMENT MULTIPLE SCLEROSIS EPILEPSY PTSD CBD BEST STRAINS FOR TREATMENT HIV PARKINSON S ALS INTRACTABLE SEIZURES

PATIENT CENTRIC Knox dispensaries are an extension of our corporate brand and products. Our goal is to provide a patient-centric environment where each person receives personalized, 1-on-1 service for their CBD and medicinal cannabis needs. Clear and easy to understand descriptions of all Knox product oerings and detailed educational resources on our proprietary products are essential discussions during each patient visit. It is imperative that each patient under- stands their physician s orders and that they leave our dispensary as educated consumers. With the support of our associates, each patient is provided training on the safety, care and utilization of their administered medical device.

CBD PRODUCTS (LESS THAN 0.8%THC) ALCOR is a sativa-dominant product that is widely used for patients with ALS, Cancer, Epilepsy, HIV/Aids, Multiple Sclerosis, Parkinson s, PTSD, and Seizures. REGOR is an indica-dominant product that produces mild relaxation for patients that need assistance with relaxing or sleeping due to chronic pain, stress, anxiety, or fatigue. This product is helpful for patients that have Chron s and Glaucoma. INDICA PRODUCTS CONSISTENCY AND QUALITY Whether your qualified patient needs CBD, Indica, Sativa, or Hybrid medicinal cannabis products, we have several options to address their qualified health condition(s). Our current line of products is available in 300 mg. or 600 mg. vaporizer cartridges or drops. By the end of 2017 our product lines will include capsules and suppositories. Due to the dierences in metabolism, one can expect a vaporizer to have an immediate eect and last 1-2 hours, while other oral formulations may take 1-2 hours to notice an eect, but last 4-6 hours. KASTOR is an indica-dominate product that supports pain relief. This product produces prolonged relaxation or sleep. POLARIS is an indica-dominate product that is helpful for patients that suer with muscle tremors and nerve pain.

HYBRID PRODUCTS ODRA is a hybrid blend that supports patients with the best of Sativa s energizing eects and Indica s ability to reduce pain. Migraine suerers will appreciate relief from intense symptoms while also experiencing a sense of deep relaxation. SATIVA PRODUCTS SUBRA is a sativa product that supports energizing and long-lasting eects for patients who need immediate but prolonged relief from stress, pain, and depression. BALDOR is a hybrid blend that is specifically designed for daytime use. This product is helpful for patients that need pain relief throughout the day without causing drowsiness or lethargy. GEMMA is a hybrid blend that reduces nausea and increases appetite. This product is well-suited for patients that are suering from the side eects of chemotherapy.

THE FIRST STEPS TO BETTER CARE FOR PROVIDERS THAT ARE INTERESTED IN RECOMMENDING MEDICINAL CANNABIS: Any licensed Florida physician with an active, unrestricted medical license must complete the Compassionate Medical Cannabis CME Course 8-hour training course and exam at http://www.flcannabisce.com/ The course and examination must be taken every 2-years prior to the renewal of the physicians Florida medical license The course is eligible for AMA PRA Category 1 Credit This course does meet the Florida Osteopathic Medical Association requirements for Florida physicians to meet their continuing education requirements online FOR PROVIDERS THAT HAVE COMPLETED THE 8-HOUR COURSE WITH THE MEDICAL ASSOCIATION: 1. Go to the Florida Department of Health website and create an account in the Compassionate Use Registry https://curegistry.flhealth.gov/ 2. New Users click on Login (Top Left) 3. Click on Register and complete the New Physician Registration Form 4. When completed click Verify Me on the bottom right of the screen. If you have any challenges with registering, please call (850) 245-4657 REGISTERING YOUR PATIENT S IN THE COMPASSIONATE USE REGISTRY 5. Immediately after a patients first visit, Register the Patient in the Compassionate Use Registry https://curegistry. flhealth.gov/ 6. Physician registers as the Ordering Physician for patient (all patient orders must be entered here- this is separate from the treatment plan) 7. Record the patients Compassionate Use Registry Number in their medical chart as you ll need this for their initial and follow-up treatment plans with the University of Florida Compassion Care Act - College of Pharmacy website 8. Immediately after treating the patient for 90-calendar days (appx. 3 oice visits), visit the University of Florida (UF) Compassionate Care Act- College of Pharmacy website and enter the patients initial treatment plan https://cca. pharmacy.ufl.edu/ Physician may not order more than 45-day supply of medical cannabis at any time If the original order is changed, physician must update the registry within 7 days after any change If the patient is under 18 years of age, second opinion is required 9. Quarterly follow-up visits are required for patient visits and they must be entered in the patients follow-up treatment plan on the University of Florida (UF) Compassionate Care Act - College of Pharmacy website https://cca.pharmacy.ufl.edu/ 10. When ordering Low-THC (CBD) or medicinal cannabis, PHYSICIAN MUST OBTAIN VOLUNTARY WRITTEN CONSENT FROM THE PATIENT OR THEIR LEGAL GUARDIAN. ALSO, THE PHYSICIAN MUST INCLUDE THE DELIVERY DEVICE IN THE ORDER, E.G. VAPE PEN.

At Knox, our mission is to compassionately provide patients with access to the highest level of medicinal cannabis in an unrivaled, professional, healthcare environment. Patient care always comes first at Knox Medical and our standards, practices, and performance is unmatched. Our coordinated team based approach provides the greatest possible outcomes for patients. Deone Canady Customer Service Manager To learn more about our organization and our medicinal cannabis products, please contact us at 888.441.KNOX (5669) or via email at info@knoxmedical.com.